Elan reports positive data on Alzheimer's drug.
Bapineuzumab is being tested in patients with mild to moderate Alzheimer's disease in two Phase II studies, Elan said. The results of the studies are not expected until 2008. More than 5 million Americans and more than 24 million people worldwide are estimated to suffer from Alzheimer's disease.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||TOP STORIES|
|Article Type:||Brief article|
|Date:||Jun 4, 2007|
|Previous Article:||Glaxo shares rebound on Avandia letter.|
|Next Article:||Novacea Inc. (Nasdaq) led advancing issues, soaring $6.06, or 85% on the week, to $13.16.|